Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1986-47-6 Chemical Structure| 1986-47-6

Structure of Tranylcypromine HCl
CAS No.: 1986-47-6

Chemical Structure| 1986-47-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tranylcypromine is a dual inhibitor of both MAO-A/B and LSD1.

Synonyms: SKF 385 hydrochloride; Tranylcypromine (hydrochloride); trans-2-Phenylcyclopropylamine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tranylcypromine HCl

CAS No. :1986-47-6
Formula : C9H12ClN
M.W : 169.65
SMILES Code : N[C@H]1[C@H](C2=CC=CC=C2)C1.[H]Cl
Synonyms :
SKF 385 hydrochloride; Tranylcypromine (hydrochloride); trans-2-Phenylcyclopropylamine
MDL No. :MFCD00063602

Safety of Tranylcypromine HCl

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P501-P270-P264-P301+P310+P330-P405
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Target
  • MAO-B

    MAO-B, IC50:7 μM

  • MAO-A

    MAO-A, IC50:11.5 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
NCI-H510A 0.002 to 2000 nM 10 days Evaluate the effect of Tranylcypromine on SCLC cell viability ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834.
Jurkat cells 10 µM 12 hours Evaluate the effect on LSD1-dependent transcriptional regulation, results showed S1427 significantly downregulated NOTCH3 expression ACS Med Chem Lett. 2022 Apr 29;13(5):848-854.
MV(4;11) 0.002 to 2000 nM 24 hours Evaluate the effect of Tranylcypromine on LSD1 target engagement ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834.
Human prostate carcinoma (LNCaP-LN3) cells 0.5, 1, 1.5, 2 mM 24, 48, 72, 96, 120 hours To investigate the effect of Tranylcypromine on cell proliferation, results showed increased proliferation in Tranylcypromine-treated cells Oncol Rep. 2013 Oct;30(4):1587-92.
Human lung epithelial cells (A549) 0.5 and 1 mM 48 hours To evaluate the antiviral effect of TCP on HSV-1 and adenovirus, results showed that TCP at 1 mM significantly reduced viral titers. Antimicrob Agents Chemother. 2014 May;58(5):2807-15.
Mouse neuronal cells (N18) 0.5 and 1 mM 48 hours To evaluate the antiviral effect of TCP on HSV-1, results showed that TCP at 1 mM significantly reduced HSV-1 titers. Antimicrob Agents Chemother. 2014 May;58(5):2807-15.
Primary astrocytes 5 µM 5.5 hours Tranylcypromine did not alter LPS-induced proinflammatory cytokine levels Cells. 2020 Aug 28;9(9):1982.
BV2 microglial cells 5 µM 5.5 hours Tranylcypromine significantly decreased LPS-induced IL-1β and IL-6 mRNA levels Cells. 2020 Aug 28;9(9):1982.
THP-1 0.002 to 2000 nM 96 hours Evaluate the effect of Tranylcypromine on CD11b marker induction ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834.
TF-1a 0.002 to 2000 nM 96 hours Evaluate the effect of Tranylcypromine on AML cell viability ACS Pharmacol Transl Sci. 2021 Nov 12;4(6):1818-1834.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Induced endometriosis model Intra-peritoneal injection 1 or 2 mg/kg Every two days for two weeks Significantly and substantially reduced the lesion size and improved generalized hyperalgesia in a dose-dependent fashion Reprod Biol Endocrinol. 2016 Apr 9;14:17
ICR mice Xenoplanted mouse cancer model Intraperitoneal injection 10 mg/5 mL/kg Single dose Evaluate pharmacokinetic profiles, results showed S1427 had significantly better AUC0?∞, Cmax, and T1/2 compared to S2157 ACS Med Chem Lett. 2022 Apr 29;13(5):848-854.
ICR mice HSV-1 infection model Topical on cornea and intraperitoneal injection 10 mg/kg Once daily for 3 days To evaluate the in vivo antiviral effect of TCP on HSV-1 infection, results showed that TCP pretreatment significantly reduced viral titers in mouse eyes. Antimicrob Agents Chemother. 2014 May;58(5):2807-15.
Male C57BL/6J mice Noise-induced permanent threshold shift hearing loss model Intraperitoneal injection 2 mg/kg Daily for 2 weeks Tranylcypromine upregulated Sestrin 2 expression, activated autophagy markers LC3B and LAMP1, reduced levels of 4-HNE and cleaved caspase-3, thereby mitigating noise-induced hair cell loss and hearing impairment. Neural Regen Res. 2025 May 1;20(5):1483-1494
Wild-type mice LPS-induced neuroinflammation model Intraperitoneal injection 3 mg/kg Daily for 3 days Tranylcypromine significantly reduced LPS-induced microglial activation and proinflammatory cytokine COX-2 and IL-6 levels Cells. 2020 Aug 28;9(9):1982.
Rats Nicotine self-administration model Intraperitoneal injection 3 mg/kg 1-hour or 20-hour pretreatment To study the mechanisms by which tranylcypromine enhances nicotine self-administration independent of MAO inhibition Neuropharmacology. 2011 Jul-Aug;61(1-2):95-104

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.89mL

1.18mL

0.59mL

29.47mL

5.89mL

2.95mL

58.94mL

11.79mL

5.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories